This use of raloxifene to combat bleeding is based on its capacity to upregulate endoglin synthesis and to modulate Alk1/Smad signaling in endothelial cells [30], with both endoglin and ALK1 known to be haploinsufficient in HHT. Here, ALK is linked to hereditary hemorrhagic telangiectasia.